Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
25.39
-0.50 (-1.93%)
At close: Aug 28, 2025, 4:00 PM
25.50
+0.11 (0.43%)
After-hours: Aug 28, 2025, 4:10 PM EDT
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2024. The number of employees increased by 8 or 12.31% compared to the previous year.
Employees
73
Change (1Y)
8
Growth (1Y)
12.31%
Revenue / Employee
$455,438
Profits / Employee
-$533,753
Market Cap
396.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 8 | 12.31% |
| Dec 31, 2023 | 65 | -3 | -4.41% |
| Dec 31, 2022 | 68 | -34 | -33.33% |
| Dec 31, 2021 | 102 | -37 | -26.62% |
| Dec 31, 2020 | 139 | 24 | 20.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ASMB News
- 20 days ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 20 days ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 20 days ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 22 days ago - Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 22 days ago - Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire
- 4 weeks ago - Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop - GlobeNewsWire
- 2 months ago - Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 - GlobeNewsWire
- 2 months ago - Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B - GlobeNewsWire